Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 02, 2020, titled "Our Associate Company, Rhizen Pharmaceuticals SA ( Rhizen ) has issued a Press Release announcing that it has received approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. ".